Fondazione IRCCS Istituto Nazionale dei Tumori
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy26 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT) | Patients With Chemotherapy-Induced Thrombocytopenia | Recruiting | Phase 3 | 2026-10-01 | NCT07286032 | |
| A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-28 | NCT06931717 | |
| Observational Study in Localized Osteosarcoma | Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, localized osteosarcoma, neoplasm, osteosarcoma, sarcoma | Recruiting | Not stated | 2026-09-02 | NCT04890067 | |
| Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-08-19 | NCT02390869 | |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2026-08-10 | NCT06731478 | |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Neoplasm, Residual, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-08-06 | NCT05232916 | |
| An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2026-07-31 | NCT05876754 | |
| LEOPARD Training and Validation Data Collection Study | Cholangitis, Sclerosing, Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholangitis, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis, primary sclerosing cholangitis | Recruiting | Not stated | 2026-07-29 | NCT06675604 | |
| Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION) | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 | 2026-07-14 | NCT02864992 | |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | childhood malignant neoplasm, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-07-10 | NCT02813135 | |
| Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2026-07-06 | NCT05948475 | |
| A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies | non-small cell lung carcinoma | Recruiting | Phase 1 / Phase 2 | 2026-07-01 | NCT05443126 | |
| Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, arthropathy, connective tissue neoplasm, disease of the tendon, giant cell tumor, muscle tissue disorder, musculoskeletal system disorder, neoplasm, synovitis, tenosynovial giant cell tumor, tenosynovial giant cell tumor, diffuse type | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-25 | NCT03069469 | |
| Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not stated | 2026-06-17 | NCT06994377 | |
| Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Active, not recruiting | Phase 3 | 2026-06-02 | NCT06625320 | |
| Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, arthropathy, connective tissue neoplasm, disease of the tendon, giant cell tumor, muscle tissue disorder, musculoskeletal system disorder, neoplasm, synovitis, tenosynovial giant cell tumor, tenosynovial giant cell tumor, diffuse type | Active, not recruiting | Phase 3 | 2026-05-04 | NCT05804045 | |
| A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, hematologic disorder, immune system disorder, immunoproliferative disorder, monoclonal gammopathy, neoplasm, precancerous condition, smoldering plasma cell myeloma | Recruiting | Not applicable | 2026-04-03 | NCT07069751 | |
| Study of Vimseltinib for Tenosynovial Giant Cell Tumor | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, arthropathy, connective tissue neoplasm, disease of the tendon, giant cell tumor, muscle tissue disorder, musculoskeletal system disorder, neoplasm, synovitis, tenosynovial giant cell tumor, tenosynovial giant cell tumor, diffuse type | Active, not recruiting | Phase 3 | 2026-03-20 | NCT05059262 | |
| Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-03-18 | NCT06726265 | |
| Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-02-05 | NCT07389265 | |
| A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, neoplasm | Active, not recruiting | Phase 3 | 2026-02-05 | NCT03673501 | |
| National Register of Actionable Mutations | Solid Tumours in Advanced Stages | Active, not recruiting | Not stated | 2026-01-30 | NCT05918666 | |
| Observational Study on Skeletal Ewing's Sarcoma | Ewing sarcoma, Ewing sarcoma of bone, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma | Recruiting | Not stated | 2026-01-02 | NCT04845893 | |
| Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen | Non Small Cell Lung Cancer NSCLC | Recruiting | Phase 2 | 2025-12-18 | NCT06680050 | |
| 5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Not yet recruiting | Phase 2 | 2025-08-15 | NCT07124884 |